Insuficiencia cardíaca: desafíos en la terapia farmacológica

Galo Juvenal Vinueza Aguay; Anthony Ricardo Chiluisa Mancheno; Christian Natanael Aveiga Flores

Authors

Galo Juvenal Vinueza Aguay Universidad Técnica de Ambato, Hospital General Docente Ambato – Tungurahua, Ecuador
Anthony Ricardo Chiluisa Mancheno Pregrado-Medicina. Universidad Técnica de Ambato – Tungurahua, Ecuador
Christian Natanael Aveiga Flores Pregrado –Medicina. Universidad Técnica de Ambato – Tungurahua, Ecuador

Keywords:

Heart failure, drug treatment, therapeutic advances, quality of life.

Abstract

Introduction: Heart Failure (HF) is a clinical entity of great importance, due to its high incidence and mortality, therefore the concern of conducting constant and updated reviews to optimize their treatment and thus impact the morbidity and mortality of patients. Objective: to critically analyze the medical literature, in the pharmacological treatment of heart failure to offer a better quality of life to the patient. Methods: documentary research through the systematic review of primary articles in scientific journals in bibliographic databases in health sciences: Pub Med, Google Scholar, Elsevier, ScienceDirect, Virtual Health Library (VHL) PAHO and Scielo, among the years of 2014 and 2018, for this the following descriptors were determined: heart failure, treatment, challenges, quality of life. 28 updated and collated digital articles were reviewed. Results: In the current treatment of heart failure, the Sacubitril / Valsartan combination prevails, since it reduces the risk of cardiovascular death by 20% and hospitalization by 21%; In addition, it reduces adverse effects in relation to conventional treatment with (ACEI). Conclusion: the new pharmacological therapies in heart failure, allow to replace conventional therapies and optimizing quality of life.

Downloads

Download data is not yet available.

References

Humaña- Giraldo HJ, Jiménez Salazar S, Buitrago Toro K, Melissa R, et al. Semiología y diagnóstico diferencial de la insuficiencia cardíaca crónica. Rev Méd Risaralda 2018; 24 (1): 49 – 57.

Deloitte Access Economics Pty Ltd © 2017. La carga de cuatro trastornos cardíacos en América Latina. [Internet] Novartis-Ecuador. [Consultado: Abril 23, 2019] Disponible en: www.deloitteaccesseconomics.com.au

Conthe P, Tejerina F. Adhesión al tratamiento y calidad de vida en los pacientes con insuficiencia cardiaca. Rev Esp Cardiol Supl. 2007; 7:57F-66F.

Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) de diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Desarrollada con la colaboración especial de la Heart Failure Association (HFA) de la ESC. Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Rev Esp Cardiol. 2016; 69(12): 1167.e1-e85. DOI: 10.1016/j.recesp.2016.10.014

Di Somma S, L. Magrini. Tratamiento farmacológico en la insuficiencia cardiaca aguda. Rev Esp Cardiol. 2015; 68(8):706–713

Chavey WE, Hogikyan RV, Van Harrison R, Nicklas JM. Heart Failure Due to Reduced Ejection Fraction: Medical Management. Am Fam Physician. 2017;95 (1):13-20.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017; 70(6):776-803.

Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33(11):1342-33.

NICE National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. NICE guideline [Internet]; 2018. [Consultado: Abril 23, 2019] Disponible en: http://www.nice.org.uk/guidance/ng106.

Lourdes Vicent AA, Vidán MT, Miguel-Yanes JM, García J, Tamargo M, et al. Perfil de la insuficiencia cardíaca en función del servicio de ingreso. Implicaciones para el manejo multidisciplinar. Rev Esp Geriatr Gerontol. 2016.

Ferreira de Oliveira F, Berretta JM, Suchi Chen E, CardosoSmith M, Ferreira Bertolucci PE. Efectos farmacogenéticos de inhibidores de la enzima convertidora de la angiotensina envariaciones de urea y creatinina asociadas con el envejecimiento en pacientes con demencia de la enfermedad de Alzheimer. Colombia Médica. 2016; 47(2): 76-80.

Crespo-Leiro MG, Segovia-Cubero J, González-Costello J, Bayes-Genis A, López-Fernández S, et al. Adecuación en España a las recomendaciones terapéuticas de la guía de la ESC sobre insuficiencia cardiaca: ESC Heart Failure Long-term Registry. Rev Esp Cardiol. 2015; 68(9):785–793.

MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7.

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and wellbeing in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295-302.

Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90.

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-9.

Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.

Trullas JC, Morales-Rull JL, Formiga F. Tratamiento diurético en la insuficiencia cardiaca. Med Clin (Barc). 2014;142(4):163–170.

García-Blas S, Bonanad C, Llàcer P, Ventura S, Núñez JM, et al. Estrategias diuréticas en insuficiencia cardiaca aguda con disfunción renal: terapia convencional frente a guiada por el antígeno carbohidrato 125. Rev Esp Cardiol. 2017;70(12): 1067-1073.

Pitt B, Remme W, Zannad F, et al. For the Eplernone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplernone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.

Volterrani M, Iellamo F. Eplerenone in chronic heart failure with depressed systolic function. Int J Cardiol. 2015;200:12-4.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61.

Yancy CW, Jessup M, Bozkurt B. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803.

Perna ER. Tratamiento de la insuficiencia cardíaca en la era de Paradigm. Rev Fed Arg Cardiol. 2016; 45 (Supl.1 IC): 3-8.

Joly J, Desai A. Sacubitril/Valsartan: From Clinical Trials to Real-world Experience. Current Treatment Options in Cardiovascular Treatment. 2018; 20(45).

Bozkurt B. What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. Current Cardiology Reports. 2018; 20(39).

Komajda M. Tratamiento farmacológico de la insuficiencia cardíaca. ¿Qué hay de nuevo? Rev Urug Cardiol 2017; 32: 312-320.

Zivlas C, Foley P. Ivabradine - well tolerated in elderly patients with systolic heart failure. Internationale Journal of Cardiology. 2017; 249: 330-331.

Pose A, Almenar L, Manzano L. Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan. Revista Clinica Española. 2017; 217(7):398.

Picco G, Rios R, Lizarraga S, Escalada H, Lama M. Soporte paliativo en la insuficiencia cardíaca: un elefante en la habitación. FMC. 2018;25(3):170-8.

Barrios V, Escobar C, Pallares V, Egocheaga MI, Lobos JM, Bover R, Gómez Doblasg JJ, Cosính J. Programa manejo de la insuficiencia cardiaca en cardiología y en atención primaria: mejorando el manejo del paciente con insuficiencia cardiaca. Semergen. 2018

Bonafede R, Manucha W. Óxido nítrico y factores relacionados a oxidación e inflamación como posibles biomarcadores de insuficiencia cardíaca. Clin Investig Arteriosclerosis. 2018;30(2): 84-94.

Sánchez-Aguilera P, Martínez Cámara A, Lázaro Salvador M. Protocolo terapéutico de la insuficiencia cardíaca aguda según el perfil del paciente. Medicine. 2017; 12(35):2136-9

Gallego Alonso-Colmenares M, Macías Bou B, Martín González L, Martínez Larrull E. Protocolo de diagnóstico y tratamiento de la insuficiencia cardiaca en Urgencias. Medicine. 2015;11(87):5223-6.